|Bid||4.10 x 1000|
|Ask||4.50 x 4000|
|Day's Range||3.8000 - 4.4100|
|52 Week Range||2.0800 - 6.9600|
|Beta (3Y Monthly)||4.15|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 4, 2019 - Mar 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.50|
ParcelPal Technology Inc (PTNYF) (PKG), ADMA Biologics Inc (ADMA), BEST Inc (BSTI), and Semiconductor Manufacturing International Corporation (SMI) represent four companies determined to innovate towards the advancement of the tech sector. Specifically, as it relates to ParcelPal, the Company saw a need and figured out a way to fill it. The Company created an on-demand marketplace where consumers can shop for anything from food to clothing.
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 12, 2019 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and.
ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announces that the Company has submitted responses to the U.S. Food and Drug Administration (“FDA”) Complete Response Letter (“CRL”) received on December 19, 2018 for BIVIGAM®’s (Intravenous Immune Globulin [Human], 10%) (“IVIG”) Prior Approval Supplement (“PAS”).
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more Read More...
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track more than 700 prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]
The U.S. Food and Drug Administration (FDA)on Wednesday declined to approve ADMA Biologics Inc's application to re-launch its immune deficiency treatment Bivigam, the company said. The FDA decision comes more than two years after the drug's previous owner suspended its production. Bivigam is a treatment given through the veins for patients with primary humoral immunodeficiency, a condition that compromises the body's ability to fight infections.
ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announces that the U.S. Food and Drug Administration (“FDA”) has issued a Complete Response Letter (“CRL”) for the drug substance Prior Approval Supplement (“PAS”) submission and previously approved the drug product PAS submission. The FDA approved ADMA’s drug product PAS submission which was comprised of fill, finish and final release information of the drug product.
ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), announces that as of the time of this press release the Company has not received any formal written communication from the U.S. Food and Drug Administration regarding BIVIGAM’s Prior Approval Supplement under the Prescription Drug User Fee Act.
NEW YORK, NY / ACCESSWIRE / December 17, 2018 / Traders News Source, a leading independent equity research, and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on ADMA Biologics, Inc. (ADMA), a biopharmaceutical company that manufactures, markets and develops specialty plasma-based biologics for the treatment of Primary Immune Deficiency Disease and the prevention and treatment of certain infectious diseases. ADMA improved the U.S. Food and Drug Administration compliance status for its manufacturing facility in Boca Raton, Florida, which allowed it to submit applications for approval for the relaunch of BIVIGAM® and the approval and launch of RI-002.
Biotech stocks staged a modest comeback this week ending along with the broader market. The week saw a spate of clinical trial results releases , sending stocks moving in either direction. The tally of ...
On a per-share basis, the Ramsey, New Jersey-based company said it had a loss of 33 cents. The results matched Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
On October 11th, ADMA Biologics, Inc. (ADMA) announced that the FDA considered the recently submitted Prior Approval Supplement (PAS) submission for Bivigam to be a major amendment and will require an additional two months for review. This change advances the target action date to December 18, 2018. In July 2018 ADMA indicated that the FDA had received their PAS filing for Bivigam and anticipated an October 25 PDUFA date.
Junior miners turned lower in sympathy with declining gold and silver contracts, while small biotech and medical diagnostic stocks picked up the slack, underpinned by sector funds probing new highs. September has a mixed reputation when it comes to small speculative plays, suggesting that traders focus their attention on penny stocks exhibiting the highest relative strength while avoiding falling knives that may face tax selling pressure in the fourth quarter. Low-priced energy stocks look like wild cards in this equation, with crude oil coming off lows while rising Middle East tensions add to sector buying power.
ADMA Biologics, Inc. (ADMA) filed its 10-K and press release for its second quarter 2018 financial results on August 10, 2018. The highlights year to date have included the release of the first commercial batch of Nabi-HB to be manufactured under ADMA ownership, the retirement of 8.6 million shares issued to Biotest and the grant of a patent for treating respiratory infections related to RI-002. On June 12, ADMA closed $40 million in equity financing followed just over six weeks later by the successful close out of the FDA compliance inspection.
On a per-share basis, the Ramsey, New Jersey-based company said it had a loss of 35 cents. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...